A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
← catalyst calendarNCT05723198 · readout ≤ 590 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
595estimated
Sites
127
Countries
Argentina, Australia, Canada +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-27 | actual | When the study began enrolling |
| Primary completion | Mar 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2033 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Areata Alopecia
- Alopecia
- Hypotrichosis
- Hair Diseases
- Skin Diseases
- Pathological Conditions, Anatomical
Interventions
- Drug: Baricitinib — also filed as LY3009104
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) ≤20
measured Week 36
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed